The influence of selective serotonin reuptake inhibitors on human platelet serotonin

 

 Buy Article Permissions and Reprints

Summary

Clinical depression has been proposed to be an independent risk factor for cardiovascular disease. While it is suggested that selective serotonin reuptake inhibitors (SSRIs) reduce the risk of acute cardiovascular problems of depressed patients, the effect of SSRIs on platelets, the only blood cells committed to serotonin (5-HT) transport, remains largely unknown. The goal of this pilot study was to measure the 5-HT levels in platelets of untreated and SSRI-treated depressed patients and normal subjects and to determine whether the interaction of SSRIs with platelets can explain their possible cardiovascular benefit in patients with depression. Platelet 5-HT was determined by an immunocytochemical assay and high-pressure liquid chromatography with electrochemical detection (HPLC-ECD). In normal control subjects without cardiovascular disease, 78 ± 8% of platelets were 5-HT-positive (n = 14). Depression caused a significant reduction in platelet 5-HT to 46 ± 21% in untreated patients (n = 13) and 22 ± 13% in SSRI-treated patients (n = 14). As a class, all selective serotonin reuptake inhibitors significantly reduced the 5-HT concentration in patient platelets. An inverse relationship of 5-HT level and dose of medication might be suggested. These results correlated well with 5-HT data from HPLC (r = 0.8509, p < 0.001). SSRIs did not affect platelet aggregation and dense granule release in response to thrombin, but significantly reduced ADP-induced platelet aggregation and dense granule release in both patient and normal control samples. The active inhibition of platelet aggregation by SSRIs might explain their cardiovascular benefit.

• References

• 1 Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin). IV. Isolation and characterization. J Biol Chem 1948; 176: 1243-51.
  PubMedGoogle Scholar
• 2 Schmuck K, Ullmer C, Kalkman HO. et al. Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache?. Eur J Neurosci 1996; 08 (05) 959-67.
  CrossrefPubMedGoogle Scholar
• 3 Srikiatkhachorn A, Suwattanasophon C, Ruangpattanatawee U. et al. 5-HT2A receptor activation and nitric oxide synthesis: a possible mechanism determining migraine attacks. Headache 2002; 42: 566-74.
  CrossrefPubMedGoogle Scholar
• 4 Sneddon JM. Blood platelets as a model for monoamine-containing neurons. Prog Neurobiol 1973; 01: 151-98.
  CrossrefPubMedGoogle Scholar
• 5 Stahl SM. The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch Gen Psychiatry 1977; 34: 509-16.
  CrossrefPubMedGoogle Scholar
• 6 Stahl SM, Meltzer HY. A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: comparison with central serotonergic neurons. Pharmacol Exp Ther 1978; 205: 118-32.
  PubMedGoogle Scholar
• 7 Plein H, Berk M. The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol 2001; 16: 229-36.
  CrossrefPubMedGoogle Scholar
• 8 White JG. Arrangements of actin filaments in the cytoskeleton of human platelets. Am J Pathol 1984; 117: 207-17.
  PubMedGoogle Scholar
• 9 Ikeda Y, Murata M, Araki Y. et al. Importance of fibrinogen and platelet membrane glycoprotein IIb/IIIa in shear-induced platelet aggregation. Thromb Res 1988; 51: 157-63.
  CrossrefPubMedGoogle Scholar
• 10 Maurer-Spurej E, Pfeiler G, Maurer N. et al. Room temperature activates human blood platelets. Lab Invest 2001; 81: 581-92.
  CrossrefPubMedGoogle Scholar
• 11 Pussard E, Guigueno N, Adam O. et al. Validation of HPLC-amperometric detection to measure serotonin in plasma, platelets, whole blood, and urine. Clin Chem 1996; 42: 1086-91.
  PubMedGoogle Scholar
• 12 Kema IP, de Vries EG, Muskiet FA. Clinical chemistry of serotonin and metabolites. J Chromatogr B Biomed Sci Appl 2000; 747: 33-48.
  CrossrefPubMedGoogle Scholar
• 13 Stokes PE. Fluoxetine: a five-year review. Clin Ther 1993; 15: 216-43.
  PubMedGoogle Scholar
• 14 Hergovich N, Aigner M, Eichler HG. et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68: 435-42.
  CrossrefPubMedGoogle Scholar
• 15 Veenstra-VanderWeele J, Anderson GM, Cook EH. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 2000; 410: 165-81.
  CrossrefPubMedGoogle Scholar
• 16 Muck-Seler D, Pivac N, Sagud M. et al. The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Progr Neuro-Psych Biol Psych 2002; 26: 1235-43.
  PubMedGoogle Scholar
• 17 Bakish D, Cavazzoni P, Chudzik J. et al. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol Psychiatry 1997; 41: 184-90.
  CrossrefPubMedGoogle Scholar
• 18 Neuger J, Wistedt B, Sinner B. et al. The effect of citalopram treatment on platelet serotonin function in panic disorders. Int Clin Psychopharmacol 2000; 15: 83-91.
  CrossrefPubMedGoogle Scholar
• 19 Blardi P, De Lalla A, Leo A. et al. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J Clin Psychopharmacol 2002; 22: 131-36.
  CrossrefPubMedGoogle Scholar
• 20 Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43: 453-61.
  CrossrefPubMedGoogle Scholar
• 21 Roose SP. Depression, anxiety, and the cardiovascular system: The psychiatrist’s perspective. J Clin Psychiatry 2001; 62: 19-23.
  CrossrefPubMedGoogle Scholar
• 22 Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease?. Am Heart J 2000; 140: 57-62.
  CrossrefPubMedGoogle Scholar
• 23 O’Connor CM, Gurbel PA, Serebruany VL. Depression and ischemic heart disease. Am Heart J 2000; 140: 63-69.
  CrossrefPubMedGoogle Scholar
• 24 Roose SP. Considerations for the use of antidepressants in patients with cardiovascular disease. Am Heart J 2000; 140: 84-88.
  CrossrefPubMedGoogle Scholar
• 25 Glassman AH, Rodriguez AI, Shapiro PA. The use of antidepressant drugs in patients with heart disease. J Clin Psychiatry 1998; 59: 16-21.
  PubMedGoogle Scholar
• 26 Glassman AH, O’Connor CM, Califf RM. et al. (SADHART group). Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-9. Corrections in JAMA 2002; 288: 1720.
  CrossrefPubMedGoogle Scholar
• 27 Cooper TA, Valcour VG, Gibbons RB. et al. Spontaneous ecchymoses due to paroxetine administration. Am J Med 1998; 104: 197-98.
  CrossrefPubMedGoogle Scholar
• 28 De Abajo FJ, Rodriguez LAG, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Br Med J 1999; 319: 1106-9.
  PubMedGoogle Scholar
• 29 Williams D, Kelly A, Feely J. Association between SSRIs and upper gastrointestinal bleeding. Brit Med J 2000; 320: 1405.
  CrossrefPubMedGoogle Scholar
• 30 Dunn NR, Pearce GL, Shakir SAW. Association between SSRIs and upper gastrointestinal bleeding. SSRIs are no more likely than other drugs to cause such bleeding. Br Med J 2000; 320: 1405-6.
  CrossrefPubMedGoogle Scholar
• 31 Ingerman-Wojenski C, Smith JB, Silver MJ. Evaluation of electrical aggregometry: comparison with optical aggregometry, secretion of ATP, and accumulation of radiolabeled platelets. J Lab Clin Med 1983; 101: 44-52.
  PubMedGoogle Scholar
• 32 McNicol A, Israels SJ. Platelet dense granules: structure, function and implications for haemostasis. Thromb Res 1999; 95: 1-18.
  CrossrefPubMedGoogle Scholar
• 33 Novak EK, Gautam R, Reddington M. et al. The regulation of platelet-dense granules by Rab27a in an ashen mouse, a model of Hermansky-Pudlak and Griscelli syndromes, is granule-specific and dependent on genetic background. Blood 2002; 100: 128-35.
  CrossrefPubMedGoogle Scholar
• 34 Maurer-Spurej E, Dyker K, Gahl WA. et al. A novel immunocytochemical assay for the detection of serotonin in platelets. Br J Haematol 2002; 116: 604-11.
  CrossrefPubMedGoogle Scholar
• 35 Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994; 40: 288-95.
  PubMedGoogle Scholar
• 36 Toth M. 5-HT(1A) receptor knockout mouse as a genetic model for anxiety. Eur J Pharmacol 2003; 463 1-3 177-84.
  CrossrefPubMedGoogle Scholar
• 37 Nemeroff CB. Recent advances in the neurobiology of depression. Psychopharmacol Bull 2002; 36: 6-23.
  PubMedGoogle Scholar
• 38 Sheehan DV. The management of panic disorder. J Clin Psychiatry 2002; 63: 17-21.
  PubMedGoogle Scholar
• 39 Kent JM, Coplan JD, Lombardo I. et al. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [(11)C]McN 5652. Psychopharmacology 2002; 164: 341-48.
  CrossrefPubMedGoogle Scholar
• 40 Mann JJ, McBride PA, Anderson GM. et al. Platelet and whole blood serotonin content in depressed inpatients: correlations with acute and life-time psychopathology. Biol Psychiatry 1992; 32: 243-57.
  CrossrefPubMedGoogle Scholar
• 41 Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993; 54: 14-34.
  PubMedGoogle Scholar
• 42 Goodnick PJ. Pharmacokinetics of second generation of antidepressants: fluoxetine. Psychopharmacol Bull 1991; 27: 503-12.
  PubMedGoogle Scholar
• 43 Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991; 41: 450-77.
  CrossrefPubMedGoogle Scholar
• 44 de Vries MH, Raghoebar M, Mathlener IS. et al. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992; 14: 493-98.
  CrossrefPubMedGoogle Scholar
• 45 Maurer-Spurej E, Devine DV. Platelet aggregation is not initiated by platelet shape change. Lab Invest 2001; 81: 1517-26.
  CrossrefPubMedGoogle Scholar
• 46 Musselman DL, Marzec U, Davidoff M. et al. Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment. Depress Anxiety 2002; 15: 91-101.
  CrossrefPubMedGoogle Scholar
• 47 Menys VC, Smith CC, Lewins P. et al. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci (Lond) 1996; 91: 87-92.
  PubMedGoogle Scholar
• 48 Pai VB, Kelly MW. Bruising associated with the use of fluoxetine. Ann Pharmacother 1996; 30: 786-88.
  CrossrefPubMedGoogle Scholar
• 49 Vandel P, Vandel S, Kantelip JP. SSRI-induced bleeding: two case reports. Therapie 2001; 56: 445-47.
  PubMedGoogle Scholar
• 50 Szasz R, Dale GL. Thrombospondin and fibrinogen bind serotonin-derivatized proteins on COAT-platelets. Blood 2002; 100: 2827-31.
  CrossrefPubMedGoogle Scholar
• 51 Hollopeter J, Jantzen H-M, Vincent D. et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
  CrossrefPubMedGoogle Scholar
• 52 Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, C17 and C270. Blood 2003; 101: 3908-14.
  CrossrefPubMedGoogle Scholar